

Dear Editor and Reviewers:

Thank you for your letter and for the reviewers' comments concerning our manuscript entitled "Prognostic value of SNX10 in stomach adenocarcinoma - revealed by WGCNA co-expression network analysis" (ID: 41325). Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval. Revised portion are marked in red in the paper. The main corrections in the paper and the responds to the reviewer's comments are as following:

Responds to the reviewer's comments:

Reviewer #1:

What is less clear to me is if the gastric adenocarcinoma patients records extracted from the Cancer Genome Atlas (TCGA) are just those which are apparently registered at present on the clinical trial website (433 cases in total) ; furthermore it should be extremely useful to know the geographical allocation of the examined patients, since it is well know that gastric cancer shows extremely different bio-clinical behaviors in the Wester and Eastern hemisphere.

Response: The latest information of gastric adenocarcinoma patients records in TCGA were public in 20160128 (TCGA-STAD). It just includes 433 cases as I mentioned in my manuscript.

Actually, it is true that the bio-clinical behaviors in the Wester and Eastern hemisphere are difference. The race distribution of STAD cases are: 278 White, 89 Asian, 13 black of African American and 63 others. Take potential bias into account, we use two Chinese-resource gastric cancer cell (SGC-7901 and BGC-823) to verify the validity of the prediction. And the 362 patient in our center are all Chinese, it was also verify the validity of the prediction. Based on these evidence, we confirm that SNX10 is a meaningful biomarker in gastric adenocarcinoma patients. We will explore the other bio-clinical behaviors in further research.

Reviewer #2:

1. The title should reveal main findings in detail. 2. Like the study of gastric cancer cell lines, it is good that the negative control tissues would be included in the study of IHC of gastric cancer tissue. 3. The figure of the negative result of IHC of SNS10 is needed.

Response: 1. We have changed the title as "Prognostic value of SNX10 weak-expression in stomach adenocarcinoma - revealed by WGCNA co-expression network analysis".

2-3. We have added the negative result of IHC of SNS10 in figure 5.